In a report published Thursday, Leerink Swann analyst Joseph P. Schwartz reiterated an Outperform rating on The Medicines Company MDCO, and raised the price target from $40.00 to $42.00.
In the report, Leerink Swann noted, “At today's analyst meeting, MDCO reviewed the status of its ongoing Angiomax patent litigation and highlighted the robust growth and diversification opportunities presented by its burgeoning interventional cardiology and hospital product pipeline. MDCO expects revenues to grow at a CAGR of >20% from 2014-2018, and we are updating our model to include $150MM in peak Fibrocaps sales in 2025 and a top-line growth rate of ~20% for the next 5 years. Reit. OP on MDCO; raising our PT to $42 from $40.”
The Medicines Company closed on Wednesday at $31.64.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in